Biotech News

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

Milestone Pharmaceuticals Inc. (MIST)Milestone Pharmaceuticals Inc.2026-06-25 13:46 ESTClinical readout

CARDAMYST™ (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoption Express Scripts national formulary coverage secured as company makes progress toward broad patient access Atrial Fibrillation-RVR Phase 3 registration trial

Open original release

Related news

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT

View all latest news

Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

MISTMilestone Pharmaceuticals Inc.2026-06-26 14:51 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MISTMilestone Pharmaceuticals Inc.2026-06-26 14:51 EST

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

MISTMilestone Pharmaceuticals Inc.2026-06-26 14:51 EST

Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

MISTMilestone Pharmaceuticals Inc.2026-06-26 14:51 EST

Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

MISTMilestone Pharmaceuticals Inc.2026-06-26 14:51 EST

Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States